生物类似药与原始药:护士关于有效性,安全性和患者护理的全面指南
Elizabeth Hughes1, Sharon Tymkiw, Karen M Vuckovic
1At Northwestern Medicine, Elizabeth Hughes is a clinical nurse and Sharon Tymkiw is a clinical nurse operations coordinator. Karen M. Vuckovic is an associate clinical professor of biobehavioral health nursing science at the University of Illinois College of Nursing.
Nursing
|January 10, 2025
概括
生物仿制药为昂贵的生物药物提供了新的治疗选择. 护士在教育患者关于生物类似药的安全性和有效性方面发挥着关键作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 患者教育 患者教育
- 获得医疗保健 获得医疗保健 获得医疗保健
背景情况:
- 生物药物是昂贵的,限制了患者的获取.
- 生物仿制药为生物制药提供了一个更实惠的替代品.
- 护士对于弥合患者对新疗法的知识差距至关重要.
研究的目的:
- 定义生物类药物和相关术语.
- 概述生物类似药的开发和批准过程.
- 为护士提供关于生物类似药的有效患者教育策略.
主要方法:
- 关于生物类似药物开发的文献综述.
- 对生物类似药的监管途径的分析.
- 综合了新疗法患者教育的最佳实践.
主要成果:
- 生物类药物经过严格的测试,以确保与参考生物药物的相似性.
- 了解开发过程可以增强对生物类似药物的安全性和有效性的信心.
- 有效的患者教育使个人能够做出明智的治疗决策.
结论:
- 生物仿制药扩大了治疗选择,并提高了药物可用性.
- 护士需要全面的知识来有效地教育患者关于生物类似药的知识.
- 患者教育对于成功将生物仿制药纳入临床实践至关重要.
相关概念视频
Bioequivalence: Overview
918
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
918
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Drug Nomenclature
1.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.6K
Nursing Clinical Information System
749
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
749
Pharmacovigilance
771
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
771
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K


